scholarly journals Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: A systematic review and meta-analysis

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0245612
Author(s):  
Xiaoting Wen ◽  
Ruihong Hou ◽  
Ke Xu ◽  
Yunxia Han ◽  
Junping Hu ◽  
...  
Keyword(s):  
Publication Bias ◽  
Takayasu Arteritis ◽  
Meta Analysis ◽  
Random Effect Model ◽  
Cochrane Library ◽  
Pentraxin 3 ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Activity Assessment ◽  
Ptx3 Level

Aims Whether the circulating levels of pentraxin 3 (PTX3), an acute phase reactant (APR), are higher in active Takayasu arteritis (TAK), and if so, whether PTX3 is more accurate than C-reactive protein (CRP) in TAK activity assessment has been investigated in this study. Study design Research works such as PubMed, Embase, ScienceDirect, Cochrane Library, and two Chinese literature databases (CNKI and WanFang) were searched for studies conducted till August 30th, 2019. Two investigators searched the studies independently, who evaluated the quality of the study using the Newcastle–Ottawa scale (NOS) and extracted data. Pooled standard mean difference (SMD) and diagnostic indexes, with a 95% confidence interval (CI), were calculated using a random-effect model. Results Totally, 8 studies involving 473 TAK (208 active and 265 inactive TAK) patients and 252 healthy controls were eventually included in the meta-analysis. PTX3 level in the blood in active TAK patients were found to be higher than that in dormant TAK with pooled SMD of 0.761 (95% CI = 0.38–1.14, p<0.0001; I2 = 68%, p of Q test = 0.003). And there was no publication bias. Among the 8 studies, 5 studies identified active TAK with both PTX3 and CRP. The pooled sensitivity, specificity, and AUC values of PTX3 in active TAK diagnosis were higher than those of CRP (0.78 [95% CI = 0.65–0.87] vs. 0.66 [95% CI = 0.53–0.77], p = 0.012; 0.85 [95% CI = 0.77–0.90] vs. 0.77 [95% CI = 0.56–0.90], p = 0.033; 0.88 [95% CI = 0.85–0.90] vs. 0.75 [95% CI = 0.71–0.79], p < 0.0001). It showed potential publication bias using Egger’s test (p of PTX3 = 0.031 and p of CRP = 0.047). Conclusions PTX3 might be better than CRP in the assessment of TAK activity. Yet, it should be cautious before clinical use for moderate heterogeneity and potential publication bias of the meta-analysis.

scholarly journals Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Zhenhua Liu ◽  
Hongtai Shi ◽  
Longyun Chen
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
Cochrane Library ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Pre Treatment

Abstract Background In recent years, the role of pre-treatment C-reactive protein/albumin ratio (CAR) in prognosis of esophageal cancer (EC) has been investigated by several studies. This meta-analysis aimed to provide a more accurate and objective assessment of the prognostic value of pre-treatment CAR in EC. Methods Studies assessing the role of pre-treatment CAR in prognosis of EC were searched from PubMed, Embase and the Cochrane Library (last update by April 16, 2019). The hazard ratios (HRs) of CAR and the corresponding 95% CIs for overall survival (OS) or cancer-specific survival (CSS) in EC were extracted for pooled analysis. Results A total of eight observational studies including 2255 patients were collected. The pooled analysis showed that high CAR was related to worse OS in EC (pooled HR = 1.81; 95% CI = 1.40–2.35; P < 0.001). Subgroup analyses showed that the negative correlation between the CAR and OS was consistently demonstrated in subgroups stratified by country, pathological type, and cut-off value (P < 0.05). However, there was no relation between CAR and OS in subgroup of patients receiving neoadjuvant chemotherapy at a proportion of 100% (HR = 1.15, 95% CI = 0.56–2.69; P = 0.715). In addition, high CAR was also related to worse CSS in EC (pooled HR = 2.61; 95% CI = 1.67–4.06; P < 0.001). Conclusions High pre-treatment CAR was an adverse prognostic factor for EC patients. More large-sample clinical trials are still needed to verify the prognostic value of pre-treatment CAR in EC.

scholarly journals Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients With Pancreatic Cancer: A Meta-Analysis

Dose-Response ◽  
2020 ◽  
Vol 18 (2) ◽  
pp. 155932582093129
Author(s):  
Qinfen Xie ◽  
Lidong Wang ◽  
Shusen Zheng
Keyword(s):  
Pancreatic Cancer ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Survival Outcomes ◽  
C Reactive Protein ◽  
Free Survival ◽  
Albumin Ratio ◽  
Reactive Protein

Background: This meta-analysis explored the correlation between the C-reactive protein to albumin ratio (CAR) and survival outcomes and clinicopathological characteristics in patients with pancreatic cancer. Methods: PubMed, Embase, Web of Science, and Cochrane Library databases were comprehensively searched through October 17, 2019. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to evaluate the association between CAR and overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) in pancreatic cancer. Results: The meta-analysis included 11 studies comprising 2271 patients. The pooled results showed that a high CAR was predictive of worse OS (HR = 1.84, 95% CI = 1.65-2.06, P < .001), PFS (HR = 1.53, 95% CI = 1.27-1.85, P < .001), and DFS (HR = 1.77, 95% CI = 1.30-2.41, P < .001). An elevated CAR was also associated with male sex (OR = 1.38, 95% CI = 1.10-1.74, P = .006). Conclusion: Elevated pretreatment CAR effectively predicts inferior survival outcomes in patients with pancreatic cancer and may be a powerful prognostic indicator for these patients.

scholarly journals Clinical Significance of C-Reactive Protein to Albumin Ratio in Patients with Hepatocellular Carcinoma: A Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Nanping Lin ◽  
Jingrong Li ◽  
Qiao Ke ◽  
Lei Wang ◽  
Yingping Cao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Clinicopathological Characteristics ◽  
Included Study ◽  
Current Data ◽  
Cochrane Library ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein

Aim. To evaluate the prognostic significance of C-reactive protein to albumin ratio (CAR) for clinical outcomes in hepatocellular carcinoma (HCC) patients. Material and Methods. Eligible studies were searched by PubMed, MedLine, the Cochrane Library, from January 1, 2000, to June 30, 2019, investigating the prognostic value of CAR in patients with HCC. Primary endpoint was OS. Hazard ratio (HR) with 95% confidence interval (CI) was used to determine the effect size. Results. 7 records including 2208 patients published since 2014 were enrolled into our meta-analysis. Clinicopathological characteristics were also correlated with the level of CAR. The pooled HR for the OS rate between low and high CAR groups was 2.13 (95% CI 1.70~2.68, P<0.00001) using a random model, but sensitivity analysis showed that the pooled HR for the OS rates did not change substantially after removal of any included study. As for patients receiving surgery, the pooled HR for the OS rate between low and high CAR groups was 2.04 (95% CI 1.59~2.61, P<0.00001). Subgroup analysis showed that CAR could be a prognostic biomarker for HCC patients regardless of regions (China, HR=1.75, 95% CI 1.51~2.02; Japan, HR=3.36, 95% CI 2.07~5.45; Korea, HR=2.26, 95% CI 1.47~4.47; respectively), the cut-off value (<0.1, HR=2.84, 95% CI 1.90~4.24; >0.1, HR=1.99, 95% CI 1.52~2.61; respectively), and sample size (<200, HR=2.85, 95% CI 2.01~4.03; >200, HR=1.75, 95% CI 1.52~2.02; respectively). Conclusion. With the current data, we clearly concluded that CAR was closely correlated with prognosis of patients with HCC. Multicenter, prospective randomized trials are warranted to confirm the conclusion.

scholarly journals A Meta-analysis of Therapeutic Effect of Thalidomide on Ankylosing Spondylitis

2020 ◽  
Vol 3 (3) ◽  
pp. 21
Author(s):  
Yukun Yao ◽  
Xin Liu
Keyword(s):  
Ankylosing Spondylitis ◽  
Therapeutic Effect ◽  
Morning Stiffness ◽  
Total Effective Rate ◽  
Meta Analysis ◽  
Effective Rate ◽  
Risk Of Bias ◽  
Cochrane Library ◽  
C Reactive Protein ◽  
Reactive Protein

Objective: To study the therapeutic effect of thalidomide on ankylosing spondylitis (AS) by meta-analysis. Methods: Personal digital library, Cochrane library, and China Biology Medicine disc (CMBdisc), as well as relevant pharmaceutical and medical journals, were collected and reviewed. After the analysis of characteristics of the selected document and the evaluation of the risk of bias, the therapeutic effect of thalidomide on ankylosing spondylitis (AS) and its influence on related indexes were analyzed by literature data. Results: The meta-analysis results of 8 pieces of literature showed that the total effective rate of thalidomide in the treatment of ankylosing spondylitis (AS) was significantly improved, compared with conventional treatment or sulfasalazine (SASP) treatment (P＜0.05). Furthermore, the time of morning stiffness, BASDAI score, C-reactive protein (CRP) level, and other related symptoms and indexes were significantly optimized (P＜0.05). Conclusion: By rational utilization of thalidomide in the treatment of ankylosing spondylitis (AS), related symptoms and indexes of patients can be effectively improved, the total effective rate of the treatment was significantly improved and the safety of the treatment can be guaranteed.

scholarly journals Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis

2012 ◽  
Vol 42 (10) ◽  
pp. 2015-2026 ◽  
Author(s):  
S. A. Hiles ◽  
A. L. Baker ◽  
T. de Malmanche ◽  
J. Attia
Keyword(s):  
Interleukin 6 ◽  
Inflammatory Markers ◽  
Antidepressant Treatment ◽  
Inflammatory Marker ◽  
Meta Analysis ◽  
Interleukin 10 ◽  
Cochrane Library ◽  
C Reactive Protein ◽  
Cross Sectional ◽  
Reactive Protein

BackgroundCross-sectional studies support an association between depression and inflammatory markers. However, little is known of their relationship in the context of antidepressant treatment. Our aim was to explore via meta-analysis whether antidepressant treatment is associated with a reduction in three inflammatory markers associated with depression.MethodA computerized search of EMBASE, Medline, PsycINFO and Cochrane Library databases was completed using subject headings for depression and either interleukin-6, C-reactive protein or interleukin-10, selecting studies which reported circulating levels of inflammatory markers before and after antidepressant treatment for people with depression. Outcome and moderator variables were coded for analysis, including inflammatory marker change, depression severity change, age, gender ratio, assay brand, treatment response and weight change.ResultsPooled effect sizes showed a significant decrease in interleukin-6 (n=14, d=−0.42, p=0.02), marginally significant decrease in C-reactive protein (n=8, d=−0.57, p=0.05) and a non-significant decrease in interleukin-10 (n=3, d=−0.45, p=0.14) after treatment. High levels of heterogeneity were observed, which may be associated with clinical variations between the studies such as weight gain, anxiety, incomplete remission and other individual differences and co-morbidities.ConclusionsThe findings of this meta-analysis indicate that there may be a normalization of overactive inflammatory processes following antidepressant treatment.

C-reactive protein with the survival outcomes of bladder cancer patients: a meta-analysis

2020 ◽  
Author(s):  
Ahouanse Roland Donald ◽  
Hailiang Ran ◽  
Die Fang ◽  
Yusan Che ◽  
Yuanyuan Xiao
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Random Effect ◽  
Random Effect Model ◽  
Disease Free Survival ◽  
C Reactive Protein ◽  
Cancer Specific Survival ◽  
Reactive Protein ◽  
Effect Model

Abstract Objectives Accumulating evidences suggested that serum C-reactive protein (CRP) was associated with the survival of bladder cancer patients. However, incongruent findings have been reported. Methods We comprehensively searched PubMed, Embase, and Web of science through August 2020 in order to find all eligible studies on the association between CRP and the overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS) of bladder cancer patients. The pooled hazard ratios (HRs) together with their 95% confidence intervals (CIs) were estimated by fixed-effect model if the heterogeneity was low, and random-effect model if the heterogeneity was high. A series of subgroup meta-analysis were performed with regard to the specific characteristics of study design. Results Thirteen eligible studies were included in this meta-analysis. The pooled results of 8 included studies revealed that an elevated CRP was associated with poor OS (HR = 2.24, 95% CI: 1.16–4.34) and CSS (HR = 1.53 95% CI: 1.36–1.72) of bladder cancer. Besides, the combined results of 3 included studies also indicated an inferior DFS for bladder cancer patients of elevated CRP level (HR = 2.07, 95% CI: 1.24–3.35). Subgroup analyses supported the robust association between elevated CRP and CSS. Conclusions These findings suggested that bladder cancer patients reported increase serum CRP had inferior prognostic outcomes.

scholarly journals C-Reactive Protein to Albumin Ratio in Colorectal Cancer: A Meta-Analysis of Prognostic Value

Dose-Response ◽  
2019 ◽  
Vol 17 (4) ◽  
pp. 155932581988981 ◽  
Author(s):  
Qiang-ping Zhou ◽  
Xiu-jiang Li
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Tumor Diameter ◽  
C Reactive Protein ◽  
Free Survival ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Serum Carcinoembryonic Antigen

Background: The relationship between pretreatment C-reactive protein to albumin ratio (CAR) and colorectal cancer (CRC) prognosis has been extensively studied in various tumors. However, little is known on CAR and its association with prognosis in CRC. This study aims to investigate the prognostic value of pretreatment CAR in CRC. Methods: We conducted a systematic search of MEDLINE, EMBASE, and Cochrane Library databases for eligible studies evaluating the associations of CAR with survival and/or clinicopathology of CRC. Overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS), and clinicopathological features were synthesized and compared. Results: Nine studies including 3431 patients were analyzed in this meta-analysis. Pooled results showed that elevated pretreatment CAR was associated with poor OS (pooled hazards ratio [HR]: 2.18, 95% confidence interval [CI]: 1.70-2.78, P < .001) and DFS/RFS (pooled HR: 2.36, 95% CI: 1.40-3.98, P < .001). Moreover, elevated pretreatment CARs were correlated with male patients, large tumor diameter, late III-IV tumor node metastasis stage tumors, high serum carcinoembryonic antigen and carbohydrate antigen 19-9, and presence of lymphatic invasion and venous invasion. Conclusion: Elevated pretreatment CAR could be an adverse prognostic indicator in patients with CRC.

Beneficiary effect of a-lipoic acid supplementation on C-reactive protein level among adults

2018 ◽  
Vol 48 (6) ◽  
pp. 1003-1019 ◽  
Author(s):  
Somaye Fatahi ◽  
Hamed Kord Varkaneh ◽  
Alireza Teymouri ◽  
Leila Azadbakht
Keyword(s):  
Lipoic Acid ◽  
Fixed Effects ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Significant Heterogeneity ◽  
C Reactive Protein ◽  
Content Type ◽  
Reactive Protein ◽  
The Impact

PurposeClinical evidence has suggested that alpha-lipoic acid (ALA), a potent antioxidant, seems to have some effects on inflammatory process. However, these results are equivocal. The purpose of this paper is to investigate the nature of association between ALA and serum C-reactive protein (CRP) level by pooling the results from clinical trial studies.Design/methodology/approachRelevant studies were identified by systematic literature search of PubMed/MEDLINE, Scopus, Web of Sciences and Cochrane library up to September 2016 for randomized controlled trials (RCTs) evaluating the impact of ALA supplementation on CRP. The pooled data were summarized as weighted mean difference (WMD) and 95 per cent confidence interval (CI). Effect sizes of eligible studies were pooled using random- or fixed-effects (the DerSimonian–Laird estimator) depending on the results of heterogeneity tests.FindingsOf 212 papers, 15 were eligible RCTs according to inclusion criteria. The selected studies comprised 1,408 cases and 457 controls. The dose of ALA supplement ranged from 300 to 1,200 mg, and the duration of follow-up was from 1 to 48 weeks. ALA supplementation significantly reduced the levels of circulating CRP (WMD: −0.088, 95 per cent CI: −0.131, −0.045,p< 0.001) with significant heterogeneity (I2= 73.4 per cent,p< 0.001). Populations with age younger than 50 years (PMD: −0.060 mg/dl), receiving doses less than 600 mg/day (PMD: −0.057 mg/dl), having cardiovascular disease (PMD: −0.105 mg/dl), hemodialysis (PMD: −0.209 mg/dl), diabetes (PMD: −0.021 mg/dl) and otherwise healthy subjects (PMD: −0.045 mg/dl) were sources of heterogeneity.Originality/ValueThis meta-analysis of RCTs suggests that ALA supplementation seems to significantly reduce circulating CRP level.

Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral Center

2013 ◽  
Vol 40 (12) ◽  
pp. 2047-2051 ◽  
Author(s):  
Enrico Tombetti ◽  
Stefano Franchini ◽  
Maurizio Papa ◽  
Maria Grazia Sabbadini ◽  
Elena Baldissera
Keyword(s):  
Takayasu Arteritis ◽  
Inflammatory Markers ◽  
Tumor Necrosis ◽  
Tnf Inhibitors ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Activity Assessment ◽  
Erythrocyte Sedimentation ◽  
Necrosis Factor ◽  
Disease Activity Assessment

Objective.The aim of our study was to evaluate the safety and the efficacy of tocilizumab (TCZ) for refractory Takayasu arteritis (TA).Methods.We retrospectively assessed the outcome of blocking interleukin (IL)-6 with TCZ in 7 consecutive patients with refractory TA using a combination of clinical and imaging assessment.Results.During a median followup visit at 14 months, 4 patients taking TCZ [including 2 nonresponders to tumor necrosis factor (TNF) inhibitors] achieved clinical response, suggesting a nonredundant role for IL-6 in TA. Inflammatory markers normalized in all patients treated with TCZ. However, vascular progression occurred in 4 patients, suggesting the involvement of other inflammatory pathways and confirming the limitations of erythrocyte sedimentation rate and C-reactive protein for disease activity assessment while taking TCZ. Three patients experienced adverse events and 2 suspended TCZ.Conclusion.TCZ may be effective in a subset of patients with refractory TA, even in cases of unresponsiveness to TNF inhibitors. Inflammatory markers are not valid markers of TA activity on TCZ. Further studies are needed to confirm these preliminary observations.

scholarly journals Meta-Analysis on the Association of C-Reactive Protein Polymorphisms with Metabolic Syndrome

2020 ◽  
Vol 07 (01) ◽  
pp. 008-013
Author(s):  
Seyedeh Maryam Sharafi ◽  
Manijeh Mahdavi ◽  
Roya Riahi ◽  
Majid Kheirollahi ◽  
Roya Kelishadi
Keyword(s):  
Metabolic Syndrome ◽  
Meta Analysis ◽  
Random Effect ◽  
Random Effect Model ◽  
P Value ◽  
Significant Heterogeneity ◽  
Nucleotide Polymorphisms ◽  
C Reactive Protein ◽  
Cross Sectional ◽  
Reactive Protein

AbstractPolymorphisms in the C-reactive protein (CRP) genes might have crucial role in the development of metabolic syndrome (MetS). In the current comprehensive meta-analyses, we aim to provide a quantitative assessment of the association between CRP single-nucleotide polymorphisms (SNPs) and the risk of MetS. An electronic search was performed on several databases. After data extraction, random effect model was used to calculate the pooled odds ratio (OR) and 95% confidence intervals (CIs). Four independent studies including case–control, cohort, and cross-sectional methods were analyzed. Our meta-analysis indicated that CRP polymorphisms are not significantly associated with MetS (OR = 0.92, 95% CI = 0.77–1.10) with significant heterogeneity (I 2 = 55.4%; p-value = 0.008). The subgroup analysis revealed that only GG has significant association with MetS (OR = 0.32, 95% CI = 0.13–0.80, p-value = 0.015) without significant heterogeneity (I 2 = 0%, p-value > 0.05). In conclusion, this meta-analysis provides strong evidence that only some SNPs of CRP gene are associated with the risk for development of MetS; and this relationship does not exist in different ethnic populations.

Sign in / Sign up

Export Citation Format

Share Document